摘要
我国鼻咽癌发病率及病死率均位居世界之首。传统的细胞毒性肿瘤治疗方法与毒性局限性密切相关,且局部晚期及复发转移鼻咽癌的病死率仍居高不下。为此靶向分子治疗成为研究热点之一,表皮生长因子受体(epidermal growth factor receptor,EGFR)及其配体的阻断是一种新型无细胞毒性的肿瘤治疗方法。尼妥珠单抗可特异性结合EGFR,阻断EGFR及其介导的下游信号传导途径,从而发挥抗肿瘤及放疗增敏作用。本文就尼妥珠单抗治疗鼻咽癌的研究进展进行综述,以期为临床工作提供参考。
The incidence and mortality of nasopharyngeal carcinoma(NPC)in China rank first in the world.The traditional cytotoxic therapy for cancer is closely related to limitations of the toxicity.The mortality of locally advanced,recurrent and metastatic NPC is still high.For this reason,targeted molecular therapy has become the hotspot of research.The blocking of epidermal growth factor receptor(EGFR)and its ligands is a new cancer treatment without cytotoxicity.nimotuzumab can specifically bind EGFR to block itself and its downstream signal transduction pathway,so as to play a role of anti-tumor and radio-sensitization.In this paper,the research progress of nimotuzumab in the treatment of NPC is summarized,so as to provide a reference for clinical practice.
作者
彭月(综述)
向志碧(审校)
Peng Yue;Xiang Zhibi(Jishou University School of Medicine,Jishou 416000,Hunan,China;First Department of Oncology,People’s Hospital of Xiangxi Tujia and Miao Autonomous Prefecture&The First Hospital Affiliated to Jishou University,Jishou 416000,Hunan,China)
出处
《肿瘤预防与治疗》
2020年第7期619-625,共7页
Journal of Cancer Control And Treatment
基金
湖南省自然科学基金(编号:S2020JJKWLH0240)。
关键词
鼻咽癌
表皮生长因子受体
尼妥珠单抗
肿瘤治疗
Nasopharyngeal carcinoma
Epidermal growth factor receptor
Nimotuzumab
Cancer treatment
